Compare IQIYI Inc - ADR (IQ) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Medpace Holdings Inc — how do they compare? IQIYI Inc - ADR trades at $1.02 (market cap $974.67M), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 17.3× IQIYI Inc - ADR's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and Medpace Holdings Inc for 14 Days on average.
| IQ | MEDP | |
|---|---|---|
Market Cap | $974.67M | $16.82B |
Volume | 4,964,108 | 223,093 |
Sector | Media | Health |
52-Week High | $2.35 | $630.19 |
52-Week Low | $0.86 | $393.42 |
Typical Hold Time | 55 Days | 14 Days |
Enterprise Value | $2.47B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQ trades at $1.025, up 0.99% today, but technicals are bearish with mixed sentiment. The company reported a net loss of $206.31M in 2025 despite beating EPS estimates in recent quarters. Revenue declined to $27.29B, and profitability metrics like ROE are negative. Analyst consensus is split with 50% buy ratings, but cash flow trends show volatility, and the firm is heavily investing in AI-driven content.
Outlook is cautious; while AI initiatives offer growth potential, core streaming pressures and persistent losses pose risks. The stock's low P/S and P/B suggest undervaluation, but investor confidence hinges on a return to profitability and successful execution of new content strategies amid competitive and macroeconomic challenges.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
